Sign in

CIK 0001806952

  • Non-accelerated filer
  • Smaller reporting company

Lyell Immunopharma, Inc.

Sign in to watch
Ticker
LYEL
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
833006753
Phone
+1 650-695-0677
Business address
201 HASKINS WAY, SOUTH SAN FRANCISCO, CA, 94080
Open-market buys, last 90 days
$49,999,983
in 2 filings
Open-market sales, last 90 days
$215,781
in 9 filings

Net +$49,784,202. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Reading 41 more Form 4s from the SEC; this list fills in as they're read.

Date Insider Transaction Shares Price Value Owned after
2025-10-27 Hill Stephen J. Chief Operating Officer Grant or award · Option (right to buy) +75,000 75,000
2025-10-27 Seely Lynn President and CEO Grant or award · Option (right to buy) +175,000 175,000
2025-08-21 Seely Lynn President and CEO Sale −7,257 $10.54 $77K 67,571
2025-08-21 Hill Stephen J. Chief Operating Officer Sale −1,004 $10.54 $11K 15,845
2025-08-21 Newton Charles W. Chief Financial Officer Sale −1,453 $10.54 $15K 15,306
2025-08-21 Lee Gary K. Chief Scientific Officer Sale −1,453 $10.54 $15K 15,504
2025-08-20 Seely Lynn President and CEO Grant or award +40,000 74,828
2025-08-20 Hill Stephen J. Chief Operating Officer Grant or award +8,000 16,849
2025-08-20 Newton Charles W. Chief Financial Officer Grant or award +8,000 16,759
2025-08-20 Lee Gary K. Chief Scientific Officer Grant or award +8,000 16,957
2025-08-12 Seely Lynn President and CEO Sale −406 $10.34 $4K 34,828
2025-08-12 Hill Stephen J. Chief Operating Officer Sale −94 $10.34 $972 8,849
2025-08-12 Lee Gary K. Chief Scientific Officer Sale −136 $10.34 $1K 8,957
2025-08-12 Newton Charles W. Chief Financial Officer Sale −136 $10.34 $1K 8,759
2025-08-11 Seely Lynn President and CEO Sale −391 $10.53 $4K 35,234
2025-08-11 Hill Stephen J. Chief Operating Officer Sale −91 $10.53 $958 8,943
2025-08-11 Lee Gary K. Chief Scientific Officer Sale −131 $10.53 $1K 9,093
2025-08-11 Newton Charles W. Chief Financial Officer Sale −131 $10.53 $1K 8,895
2025-06-09 Bachleda Mark Director Grant or award · Option (right to buy) +13,000 13,000
2025-06-09 Meltz Mark A General Counsel Grant or award · Option (right to buy) +100,000 100,000

Page 4 of 8 · 156 trades